Ulcerative Colitis (UC)

Immunology·MeSH: Colitis, Ulcerative

Prevalence

263.0 / 100K

Incidence

9.0 / 100K/yr

18 drugs in development·14 companies·12 clinical trials

Drug Pipeline by Phase

Approved(2)

Drug	Company
velsipity	PFIZER INC (PFE)
xeljanz xr	PFIZER INC (PFE)

Phase 3(2)

Drug	Company
ozanimod	BRISTOL MYERS SQUIBB CO (BMY)
ozanimod	CELGENE CORP /DE/ (CELG)

Phase 2(8)

Phase 1(3)

Drug	Company
pali-2108	PALISADE BIO, INC. (PALI)
pt101	Pandion Therapeutics, Inc. (PAND)
SER-301	Seres Therapeutics, Inc. (MCRB)

Preclinical(2)

Drug	Company
eq504	Equillium, Inc. (EQ)
ser-603	Seres Therapeutics, Inc. (MCRB)

Phase 1/Phase 2(1)

Drug	Company
XmAb942	Xencor Inc (XNCR)

BioSniper tracks 18 drugs in development for Ulcerative Colitis (UC) across 14 companies.

There are 12 clinical trials targeting Ulcerative Colitis (UC) tracked by BioSniper.

The estimated prevalence of Ulcerative Colitis (UC) is approximately 263.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.